# US 2020/0138967 A1 · Combination therapy using anti-ssea-4 antibody in combination with therapeutic oncology agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138967 A1
- Document ID: US20200138967A1
- Status: Published application
- Kind: A1
- Application number: 16/590,967
- Filed: 2019-10-02
- Published: 2020-05-07
- Earliest claimed: 2018-10-02
- Assignees: Obi Pharma, Inc.
- Applicants: Obi Pharma, Inc.
- Inventors: Cheng-Der Tony YU; Jiann-Shiun LAI; Yi-Chien TSAI
- Web page: https://patentgrep.com/patent/US20200138967A1

## CPC

- A61K 47/6425: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
- A61K 47/6853: {Carcino-embryonic antigens}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- C07K 16/2815: {against CD8}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure is generally directed to treatment methods and compositions comprising administering anti-SSEA-4 antibodies; alone or in additive and/or synergistic combination with other therapeutic agents in oncology to enhance therapeutic efficacy whereby the interaction alters the epitope binding of Siglec-9 protein; including human Siglec-9 or a mammalian Siglec-9; wherein the use of such anti-SSEA-4 compositions are efficacious in preventing, reducing risk, or treating an individual with cancer.

## Claims

### Claim 1

A method of treating a subject having a cancer cell expressing a SSEA-4 antigen, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the binding of anti-SSEA-4 antibody to the cancer cell decreases binding interaction between SSEA-4 and Siglec-9.

### Claim 3 (depends on 2)

The method of claim 2, wherein the decrease in the binding interaction between SSEA-4 and Siglec-9 results in the decrease binding of Siglec-9 to cancer cells.

### Claim 4 (depends on 3)

The method of claim 3, wherein the decrease binding of Siglec-9 to cancer cells induces a release of the immunosuppression (immune-masking) maintained by Siglec-9/SSEA-4 engagement.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administering of the anti-SSEA-4 antibody increases the activity of cytotoxic immune cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cytotoxic immune cell is an monocyte, neutrophil, NK cell, B cell or CD8+ T cell.

### Claim 7 (depends on 5)

The method of claim 5, wherein the anti-SSEA-4 antibody is OBI-898.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is selected from sarcoma, skin cancer, leukemia, lymphoma, brain cancer, lung cancer, breast cancer, oral cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, pancreas cancer, colon cancer, kidney cancer, cervix cancer, ovary cancer and prostate cancer. In certain embodiments, the cancer is sarcoma, skin cancer, leukemia, lymphoma, brain cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, or pancreas cancer. In some preferred embodiments, the cancer is brain cancer or glioblastoma multiforme (GBM) cancer.

### Claim 9

A method of activating an innate cytotoxicity immune response by inhibiting binding of a Siglec-9 expressing cytotoxic immune cell bound to a SSEA-4 antigen on a cancer cell, the method comprising contacting the cytotoxic immune cell-cancer cell complex with an antagonist of SSEA-4; and disrupting or inhibiting binding of Siglec-9 to SSEA-4.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antagonist is an SSEA-4 antibody.

### Claim 11 (depends on 10)

The method of claim 10, wherein the anti-SSEA-4 antibody is OBI-898.

### Claim 12 (depends on 9)

The method of claim 9, wherein the cytotoxic immune cell is an monocyte, neutrophil, NK cell, B cell or CD8+ T cell.

### Claim 13 (depends on 9)

The method of claim 9, wherein the cancer is selected from sarcoma, skin cancer, leukemia, lymphoma, brain cancer, lung cancer, breast cancer, oral cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, pancreas cancer, colon cancer, kidney cancer, cervix cancer, ovary cancer and prostate cancer. In certain embodiments, the cancer is sarcoma, skin cancer, leukemia, lymphoma, brain cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, or pancreas cancer. In some preferred embodiments, the cancer is brain cancer or glioblastoma multiforme (GBM) cancer.

### Claim 14

A method of treating a subject having a cancer cell expressing a SSEA-4 antigen, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof, whereby the binding of Siglec-9 to cancer cells is inhibited.

### Claim 15

A method of reducing the binding of Siglec-9 to cancer cells, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof.

### Claim 16

A method of treating a subject having a cancer cell expressing a SSEA-4 antigen, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof, whereby the activity of the cytotoxic immune cells is activated.

### Claim 17

A method of increasing the activity of the cytotoxic immune cells in a subject having a cancer, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof.

### Claim 18 (depends on 14, 15, 16, 17)

The method of claims 14-17, wherein the anti-SSEA-4 antibody is OBI-898.

### Claim 19 (depends on 16, 17)

The method of claims 16-17, wherein the cytotoxic cell is an monocyte, neutrophil, NK cell, B cell or CD8+ T cell.

### Claim 20 (depends on 14, 15, 16, 17)

The method of claims 14-17, wherein the cancer is selected from sarcoma, skin cancer, leukemia, lymphoma, brain cancer, lung cancer, breast cancer, oral cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, pancreas cancer, colon cancer, kidney cancer, cervix cancer, ovary cancer and prostate cancer. In certain embodiments, the cancer is sarcoma, skin cancer, leukemia, lymphoma, brain cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, or pancreas cancer. In some preferred embodiments, the cancer is brain cancer or glioblastoma multiforme (GBM) cancer.
